367 related articles for article (PubMed ID: 16711513)
1. Clinical utility of hyperglycosylated hCG in serum taken before hydatidiform mole evacuation to predict persistent trophoblastic disease.
Duc HN; van Trommel NE; Sweep FC; Massuger LF; Thomas CM
Int J Biol Markers; 2006; 21(1):45-9. PubMed ID: 16711513
[TBL] [Abstract][Full Text] [Related]
2. Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG {alpha}- and {beta}-subunits, and their ratios.
van Trommel NE; Sweep FC; Schijf CP; Massuger LF; Thomas CM
Eur J Endocrinol; 2005 Oct; 153(4):565-75. PubMed ID: 16189178
[TBL] [Abstract][Full Text] [Related]
3. Comparison of human chorionic gonadotropin +beta and invasive trophoblast antigen disappearance rates in serum after evacuation of molar pregnancy.
Van Trommel NE; Sweep FC; Ross HA; Massuger LF; Thomas CM
Int J Mol Med; 2006 Oct; 18(4):705-11. PubMed ID: 16964426
[TBL] [Abstract][Full Text] [Related]
4. Pre-evacuation hCG glycoforms in uneventful complete hydatidiform mole and persistent trophoblastic disease.
Thomas CM; Kerkmeijer LG; Ariaens HJ; van der Steen RC; Massuger LF; Sweep FC
Gynecol Oncol; 2010 Apr; 117(1):47-52. PubMed ID: 20116088
[TBL] [Abstract][Full Text] [Related]
5. Early identification of persistent trophoblastic disease with serum hCG concentration ratios.
van Trommel NE; Ngo Duc H; Massuger LF; Schijf CP; Sweep CG; Thomas CM;
Int J Gynecol Cancer; 2008; 18(2):318-23. PubMed ID: 17511799
[TBL] [Abstract][Full Text] [Related]
6. Clinical features of early-stage nonhydropic mole for diagnosis of persistent trophoblastic disease.
Miyoshi J; Ohba T; Fukunaga M; Katabuchi H
Obstet Gynecol; 2011 Oct; 118(4):847-53. PubMed ID: 21934448
[TBL] [Abstract][Full Text] [Related]
7. Gestational trophoblastic diseases - clinical guidelines for diagnosis, treatment, follow-up, and counselling.
Niemann I; Vejerslev LO; Frøding L; Blaakær J; Maroun LL; Hansen ES; Grove A; Lund H; Havsteen H; Sunde L
Dan Med J; 2015 Nov; 62(11):A5082. PubMed ID: 26522484
[TBL] [Abstract][Full Text] [Related]
8. Linear regression of postevacuation serum human chorionic gonadotropin concentrations predicts postmolar gestational trophoblastic neoplasia.
Lybol C; Sweep FC; Ottevanger PB; Massuger LF; Thomas CM
Int J Gynecol Cancer; 2013 Jul; 23(6):1150-6. PubMed ID: 23714707
[TBL] [Abstract][Full Text] [Related]
9. Serum Human Chorionic Gonadotropin Normogram for the Detection of Gestational Trophoblastic Neoplasia.
Eysbouts Y; Brouwer R; Ottevanger P; Massuger L; Sweep F; Thomas C; van Herwaarden A
Int J Gynecol Cancer; 2017 Jun; 27(5):1035-1041. PubMed ID: 28498241
[TBL] [Abstract][Full Text] [Related]
10. Recurrent gestational trophoblastic disease after hCG normalization following hydatidiform mole in The Netherlands.
Kerkmeijer LG; Wielsma S; Massuger LF; Sweep FC; Thomas CM
Gynecol Oncol; 2007 Jul; 106(1):142-6. PubMed ID: 17462723
[TBL] [Abstract][Full Text] [Related]
11. Identification of patients with persistent trophoblastic disease after complete hydatidiform mole by using a normal 24-hour urine hCG regression curve.
van Cromvoirt SM; Thomas CM; Quinn MA; McNally OM; Bekkers RL
Gynecol Oncol; 2014 Jun; 133(3):542-5. PubMed ID: 24631700
[TBL] [Abstract][Full Text] [Related]
12. Identification of patients with persistent trophoblastic disease by means of a normal human chorionic gonadotropin regression curve.
Yedema KA; Verheijen RH; Kenemans P; Schijf CP; Borm GF; Segers MF; Thomas CM
Am J Obstet Gynecol; 1993 Mar; 168(3 Pt 1):787-92. PubMed ID: 7681253
[TBL] [Abstract][Full Text] [Related]
13. Utility of commonly used commercial human chorionic gonadotropin immunoassays in the diagnosis and management of trophoblastic diseases.
Cole LA; Shahabi S; Butler SA; Mitchell H; Newlands ES; Behrman HR; Verrill HL
Clin Chem; 2001 Feb; 47(2):308-15. PubMed ID: 11159780
[TBL] [Abstract][Full Text] [Related]
14. Radioimmunoassay of the serum free beta-subunit of human chorionic gonadotropin in trophoblastic disease.
Fan C; Goto S; Furuhashi Y; Tomoda Y
J Clin Endocrinol Metab; 1987 Feb; 64(2):313-8. PubMed ID: 2432080
[TBL] [Abstract][Full Text] [Related]
15. Plasma human chorionic gonadotropin disappearance in hydatidiform mole: a central registry report from the Netherlands.
Franke HR; Risse EK; Kenemans P; Houx PC; Stolk JG; Vooijs GP
Obstet Gynecol; 1983 Oct; 62(4):467-73. PubMed ID: 6888825
[TBL] [Abstract][Full Text] [Related]
16. Persistent trophoblast disease following partial molar pregnancy.
Wielsma S; Kerkmeijer L; Bekkers R; Pyman J; Tan J; Quinn M
Aust N Z J Obstet Gynaecol; 2006 Apr; 46(2):119-23. PubMed ID: 16638033
[TBL] [Abstract][Full Text] [Related]
17. Prediction of persistent gestational trophobalstic neoplasia: the role of hCG level and ratio in 2 weeks after evacuation of complete mole.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2012 Feb; 124(2):250-3. PubMed ID: 22094931
[TBL] [Abstract][Full Text] [Related]
18. Inhibin as a marker for hydatidiform mole: a comparative study with the determinations of intact human chorionic gonadotrophin and its free beta-subunit.
Badonnel Y; Barbé F; Legagneur H; Poncelet E; Schweitzer M
Clin Endocrinol (Oxf); 1994 Aug; 41(2):155-62. PubMed ID: 7523000
[TBL] [Abstract][Full Text] [Related]
19. Combined analysis of clinical features, human chorionic gonadotropin (hCG) value, and hCG ratios for early prediction of postmolar gestational trophoblastic neoplasia.
Rakprasit C; Ruengkhachorn I; Therasakvichya S; Inthasorn P; Achariyapota V; Kuljarasnont S; Khemworapong K; Jareemit N
Arch Gynecol Obstet; 2023 Apr; 307(4):1145-1154. PubMed ID: 36116082
[TBL] [Abstract][Full Text] [Related]
20. Persistent gestational trophoblastic tumour with partial hydatidiform mole as the antecedent pregnancy.
Chen RJ; Huang SC; Chow SN; Hsieh CY; Hsu HC
Br J Obstet Gynaecol; 1994 Apr; 101(4):330-4. PubMed ID: 8199080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
